Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Taysha Gene Therapies, Inc. (Nasdaq: TSHA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases, Taysha uses these filings to report on its financial condition, capital-raising activities and material developments in its TSHA-102 Rett syndrome program.
Here, users can review Form 8-K current reports in which Taysha describes material events such as amendments to its at-the-market Sales Agreement for common stock, public follow-on offerings, and key press releases. Recent 8-K filings have incorporated announcements on FDA Breakthrough Therapy designation for TSHA-102, alignment on the REVEAL pivotal trial protocol and statistical analysis plan, and the company’s regaining of full rights to its lead TSHA-102 program.
Investors can also use this page to locate references to quarterly and annual financial results, which are furnished as exhibits to 8-K filings, and to understand how Taysha is funding BLA-enabling manufacturing, REVEAL and ASPIRE clinical trial activities, and general corporate operations. The filings identify TSHA as a Nasdaq-listed issuer with common stock registered under Section 12(b) of the Exchange Act and outline the structure of its equity offering programs.
Stock Titan enhances these regulatory documents with AI-powered summaries that explain the key points of lengthy filings in clear language. Users can quickly see what each 8-K covers, track changes to capital programs and material agreements, and follow how clinical and regulatory milestones for TSHA-102 are reflected in Taysha’s official SEC record. Real-time updates from EDGAR, along with structured views of exhibits and items, help readers navigate the company’s filing history efficiently.
RTW Investments, LP and Roderick Wong report beneficial ownership of 25,183,287 shares of Taysha Gene Therapies, Inc., representing approximately 9.99% of the outstanding common stock. The reported holdings reflect shared voting and shared dispositive power over the 25.18 million shares and include warrants to purchase 161,703 shares that were counted at their maximum exercisable amount but which cannot be exercised to increase beneficial ownership above the 9.99% threshold. The filing states these shares are held by RTW-managed funds and that RTW Master Fund Ltd. has the right to receive dividends or sale proceeds for more than 5% of the class. The filing is submitted on a Schedule 13G amendment and characterizes the position as held in the ordinary course of business.
Taysha Gene Therapies reported a strengthened balance sheet after a May 2025 underwritten offering that generated approximately $215.6 million in net proceeds, increasing cash and cash equivalents to $312.8 million and total assets to $333.3 million as of June 30, 2025. The company reported a net loss of $48.4 million for the six months ended June 30, 2025, which translates to a loss per share of $0.17 on a weighted-average share base of 283.7 million; research and development and general and administrative expenses totaled $52.5 million for the six-month period.
The company recognized $4.3 million of revenue related to Rett research and development activities in the six months, and deferred revenue related to the Astellas option totaled $5.5 million as of June 30, 2025. Taysha recorded the Trinity term loan at fair value and continues to mark the loan and a related success fee to market; the company stated it believes existing cash will be sufficient to fund planned operations for at least twelve months from issuance of these financial statements.
Taysha Gene Therapies disclosed that it furnished a press release reporting financial results and business highlights for the quarter ended June 30, 2025. The filing states the press release is included as Exhibit 99.1 and that the cover page interactive XBRL file is provided as Exhibit 104. The company notes the information in Item 2.02 (including Exhibit 99.1) is being furnished and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
This report identifies the exhibits attached but does not present the detailed financial figures within the body of the 8-K itself; investors should consult Exhibit 99.1 for the full results and disclosures.
Morgan Stanley and subsidiary Morgan Stanley Capital Services LLC filed Amendment No. 1 to Schedule 13G reporting a passive stake in Taysha Gene Therapies, Inc. (TSHA) as of 30 Jun 2025.
The filing discloses 16,858,644 common shares, equal to 6.7 % of the outstanding class (CUSIP 877619106). Voting and dispositive authority are entirely shared: 16,651,747 shares with shared voting power and 16,858,644 shares with shared dispositive power; neither entity claims sole authority. Morgan Stanley is classified as a holding company/control person, while Morgan Stanley Capital Services LLC is a broker-dealer. The securities are held in the ordinary course of business with no intent to influence control of the issuer.
The Schedule 13G filed on 27 June 2025 discloses that The Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC have acquired beneficial ownership of 12,748,968 shares of Taysha Gene Therapies, Inc. (TSHA) common stock. The position represents 5.1 % of TSHA’s outstanding shares, crossing the 5 % reporting threshold under Section 13(d) of the Securities Exchange Act.
All voting and dispositive authority over the shares is reported as shared; neither entity claims sole authority. The filing is on Schedule 13G, indicating a passive investment rather than an effort to influence control, as confirmed by the Item 10 certification.
Goldman Sachs & Co. LLC is classified as a broker-dealer, other organization, and investment adviser, while The Goldman Sachs Group, Inc. is identified as a holding company/control person. No additional group members or activist exhibits are included.
The disclosure confirms meaningful institutional ownership by a globally recognized financial institution, potentially improving share liquidity and lending credibility to TSHA. However, because it is a passive filing, it does not imply forthcoming strategic or operational changes at the issuer.